ReviewFrontiers in behavioral neuroscience2022
Tryptophan metabolites in depression: Modulation by gut microbiota.
Review in Frontiers in behavioral neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- The effect of Vagus nerve stimulation (VNS) on seizure control, cognitive function, and quality of life in individuals with drug-resistant epilepsy: A systematic review article.Epilepsia open · 2024Pooled it
- The effect of prebiotic supplementation on serum levels of tryptophan and kynurenine in obese women with major depressive disorder: a double-blinded placebo-controlled randomized clinical trial.BMC research notes · 2024Trial
- Integrated metagenomic and metabolomic analysis identifies severity-specific inflammatory and metabolic signatures in post-stroke depression.Gut microbes · 2026Article
- The gut neuroepithelial unit as a neurodegeneration-relevant interface in the gut-brain axis.Translational neurodegeneration · 2026Review
- Dietary Tryptophan Allocation in Depression: Serotonin-Kynurenine Balance, Microbial Indole Pathways, and Inflammatory Phenotypes.Nutrients · 2026Review
- From association to causality: mechanistic pathways linking the gut microbiome to psychiatric disorders.Translational psychiatry · 2026Review
- Seasonal Affective Disorder and the Microbiota-Gut-Brain Axis: Circadian Disruption, Tryptophan Metabolism, and Psychobiotic Potential ofNutrients · 2026Review
- From dysbiosis to metabolic vulnerability: implications for precision psychiatry in depression.Molecular psychiatry · 2026Article
- Psychiatric Symptoms Associated with Non-Celiac Gluten Sensitivity: A Focused Narrative Review.Nutrients · 2026Review
- Microbiome-Informed Precision Electroconvulsive Therapy: Oral-Gut-Immune Signatures and Seizure Biology as Candidate Predictors of Response-A Narrative Review.Biomedicines · 2026Review
- Depressive symptoms in chronic kidney disease: the hidden role of uremic toxins.BMJ mental health · 2026Article
- Sex-specific microbial and tryptophan signatures of depression implicate archaeal methanogens and indole-3-acetic acid only in women.NPJ biofilms and microbiomes · 2026Article
- From Plate to Mind: Scientific Perspectives on Foods That May Influence Anxiety and Depression.Nutrients · 2026Review
- Gut microbiota alterations and signatures across subthreshold depression and major depressive disorders in adolescents.Journal of translational medicine · 2026Article
- Molecular mechanisms and therapeutic potential of tryptophan metabolism in gut-brain signaling transduction: a narrative review.Journal of neuroinflammation · 2026Review
- Role of Gut Microbiota in Psychiatric Disorders: From Mechanistic Insights to Therapeutic Strategies.Journal of Korean medical science · 2026Review
- Gut Microbiota-Non-Coding RNA Axis in Immune Modulation and Disease: From Mechanisms to Clinical Translation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Integrative mechanisms and intervention targets of the microbiota-gut-brain axis in depressive disorders: advances across immune, endocrine, and central nervous system pathways.Frontiers in psychiatry · 2026Review
- Beyond the 'second brain': the gut microbiota as a constitutive co-constructor of embodied cognitive network.Frontiers in neuroscience · 2026Review
- Therapeutic impact of Mongolian Andai therapy on gut microbiota and metabolomic profiles in depression.Frontiers in neuroscience · 2026Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical depression is a multifactorial disorder and one of the leading causes of disability worldwide. The alterations in tryptophan metabolism such as changes in the levels of serotonin, kynurenine, and kynurenine acid have been implicated in the etiology of depression for more than 50 years. In recent years, accumulated evidence has revealed that gut microbial communities, besides being essential players in various aspects of host physiology and brain functioning are also implicated in the etiology of depression, particularly through modulation of tryptophan metabolism. Therefore, the aim of this review is to summarize the evidence of the role of gut bacteria in disturbed tryptophan metabolism in depression. We summed up the effects of microbiota on serotonin, kynurenine, and indole pathway of tryptophan conversion relevant for understanding the pathogenesis of depressive behavior. Moreover, we reviewed data regarding the therapeutic effects of probiotics, particularly through the regulation of tryptophan metabolites. Taken together, these findings can open new possibilities for further improvement of treatments for depression based on the microbiota-mediated modulation of the tryptophan pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.